X90 Stock Overview
Develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ProBiotix Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.051 |
| 52 Week High | UK£0.10 |
| 52 Week Low | UK£0.021 |
| Beta | -0.11 |
| 11 Month Change | 12.22% |
| 3 Month Change | 50.75% |
| 1 Year Change | -6.48% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| X90 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -24.6% | -0.2% | 0.8% |
| 1Y | -6.5% | -16.9% | 9.1% |
Return vs Industry: X90 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: X90 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| X90 volatility | |
|---|---|
| X90 Average Weekly Movement | 31.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: X90's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: X90's weekly volatility has increased from 21% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 7 | Steen Andersen | probiotixhealth-ir.com |
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. It offers YourBiotix CH and InstaMelt, capsule formula which contains LPLDL for maintenance of healthy cholesterol; YourBiotix BP, a blood pressure-reducing tablet formula for hypertension and cardiovascular health; and YourBiotix VH, a vascular health capsule formula, indicated to work against the build-up of lipid and calcium deposits in the blood vessels. The company was formerly known as ProBiotix Health Limited and changed its name to ProBiotix Health Plc in February 2022.
ProBiotix Health Plc Fundamentals Summary
| X90 fundamental statistics | |
|---|---|
| Market cap | €9.48m |
| Earnings (TTM) | -€594.53k |
| Revenue (TTM) | €2.55m |
3.7x
P/S Ratio-15.9x
P/E RatioIs X90 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X90 income statement (TTM) | |
|---|---|
| Revenue | UK£2.13m |
| Cost of Revenue | UK£955.00k |
| Gross Profit | UK£1.17m |
| Other Expenses | UK£1.67m |
| Earnings | -UK£496.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0031 |
| Gross Margin | 55.10% |
| Net Profit Margin | -23.32% |
| Debt/Equity Ratio | 0% |
How did X90 perform over the long term?
See historical performance and comparison